-
1
-
-
0023712476
-
The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae
-
Weinert TA, Hartwell LH (1988) The RAD9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science 241:317-322
-
(1988)
Science
, vol.241
, pp. 317-322
-
-
Weinert, T.A.1
Hartwell, L.H.2
-
2
-
-
0024425887
-
Checkpoints: Controls that ensure the order of cell cycle events
-
Hartwell LH, Weinert TA (1989) Checkpoints: controls that ensure the order of cell cycle events. Science 246:629-634 (Pubitemid 19283354)
-
(1989)
Science
, vol.246
, Issue.4930
, pp. 629-634
-
-
Hartwell, L.H.1
Weinert, T.A.2
-
3
-
-
0031003783
-
Maintaining genetic stability through TP53 mediated checkpoint control
-
Wahl GM, Linke SP, Paulson TG, Huang LC (1997) Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv 29:183-219 (Pubitemid 27262247)
-
(1997)
Cancer Surveys
, vol.29
, pp. 183-219
-
-
Wahl, G.M.1
Linke, S.P.2
Paulson, T.G.3
Huang, L.-C.4
-
4
-
-
0035449355
-
Cell cycle checkpoint signaling through the ATM and ATR kinases
-
Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15:2177-2196
-
(2001)
Genes Dev
, vol.15
, pp. 2177-2196
-
-
Abraham, R.T.1
-
5
-
-
33745954330
-
BCL2 family in DNA damage and cell cycle control
-
DOI 10.1038/sj.cdd.4401987, PII 4401987
-
Zinkel S, Gross A, Yang E (2006) BCL2 family in DNA damage and cell cycle control. Cell Death Differ 13:1351-1359 (Pubitemid 44057470)
-
(2006)
Cell Death and Differentiation
, vol.13
, Issue.8
, pp. 1351-1359
-
-
Zinkel, S.1
Gross, A.2
Yang, E.3
-
7
-
-
0033913696
-
Inhibition of CDKs as a therapeutic modality
-
Sausville EA, Johnson J, Alley M, Zaharevitz D, Senderowicz AM (2000) Inhibition of CDKs as a therapeutic modality. Ann N Y Acad Sci 910:207-221
-
(2000)
Ann N Y Acad Sci
, vol.910
, pp. 207-221
-
-
Sausville, E.A.1
Johnson, J.2
Alley, M.3
Zaharevitz, D.4
Senderowicz, A.M.5
-
8
-
-
0033399453
-
Anticancer drug targets: Cell cycle and checkpoint control
-
Shapiro GI, Harper JW (1999) Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest 104:1645-1653 (Pubitemid 30053178)
-
(1999)
Journal of Clinical Investigation
, vol.104
, Issue.12
, pp. 1645-1653
-
-
Shapiro, G.I.1
Harper, J.W.2
-
9
-
-
0028990479
-
Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2
-
Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA (1995) Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 6:927-936
-
(1995)
Cell Growth Differ
, vol.6
, pp. 927-936
-
-
Wang, Q.1
Worland, P.J.2
Clark, J.L.3
Carlson, B.A.4
Sausville, E.A.5
-
10
-
-
0034053130
-
The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
-
DOI 10.1074/jbc.275.8.5600
-
Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H (2000) The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275:5600-5605 (Pubitemid 30115197)
-
(2000)
Journal of Biological Chemistry
, vol.275
, Issue.8
, pp. 5600-5605
-
-
Graves, P.R.1
Yu, L.2
Schwarz, J.K.3
Gales, J.4
Sausville, E.A.5
O'Connor, P.M.6
Piwnica-Worms, H.7
-
11
-
-
2242421834
-
Structural basis for Chk1 inhibition by UCN-01
-
DOI 10.1074/jbc.M201233200
-
Zhao B, Bower MJ, McDevitt PJ, Zhao H, Davis ST, Johanson KO, Green SM, Concha NO, Zhou BB (2002) Structural basis for Chk1 inhibition by UCN-01. J Biol Chem 277:46609-46615 (Pubitemid 35417660)
-
(2002)
Journal of Biological Chemistry
, vol.277
, Issue.48
, pp. 46609-46615
-
-
Zhao, B.1
Bower, M.J.2
McDevitt, P.J.3
Zhao, H.4
Davis, S.T.5
Johanson, K.O.6
Green, S.M.7
Concha, N.O.8
Zhou, B.-B.S.9
-
12
-
-
0029895439
-
2 checkpoint function in cancer cells with disrupted p53
-
DOI 10.1093/jnci/88.14.956
-
Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM (1996) UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88:956-965 (Pubitemid 26239383)
-
(1996)
Journal of the National Cancer Institute
, vol.88
, Issue.14
, pp. 956-965
-
-
Wang, Q.1
Fan, S.2
Eastman, A.3
Worland, P.J.4
Sausville, E.A.5
O'Connor, P.M.6
-
13
-
-
0032145499
-
1-acid glycoprotein
-
Fuse E, Tanii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki Y, Tanigawara Y, Lush RD, Headlee D, Figg WD, Arbuck SG, Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S (1998) Unpredicted clinical pharmacology of UCN- 01 caused by specific binding to human alpha1-acid glycoprotein. Cancer Res 58:3248-3253 (Pubitemid 28371060)
-
(1998)
Cancer Research
, vol.58
, Issue.15
, pp. 3248-3253
-
-
Fuse, E.1
Tanii, H.2
Kurata, N.3
Kobayashi, H.4
Shimada, Y.5
Tamura, T.6
Sasaki, Y.7
Tanigawara, Y.8
Lush, R.D.9
Headlee, D.10
Figg, W.D.11
Arbuck, S.G.12
Senderowicz, A.M.13
Sausville, E.A.14
Akinaga, S.15
Kuwabara, T.16
Kobayashi, S.17
-
14
-
-
0035871444
-
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms
-
Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM (2001) Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19:2319-2333 (Pubitemid 32366984)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.8
, pp. 2319-2333
-
-
Sausville, E.A.1
Arbuck, S.G.2
Messmann, R.3
Headlee, D.4
Bauer, K.S.5
Lush, R.M.6
Murgo, A.7
Figg, W.D.8
Lahuse, T.9
Jaken, S.10
Jing, X.-X.11
Roberge, M.12
Fuse, E.13
Kuwabara, T.14
Senderowicz, A.M.15
-
15
-
-
0037034928
-
Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine)
-
DOI 10.1038/sj/onc/1205225
-
Sato S, Fujita N, Tsuruo T (2002) Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21:1727-1738 (Pubitemid 34259036)
-
(2002)
Oncogene
, vol.21
, Issue.11
, pp. 1727-1738
-
-
Sato, S.1
Fujita, N.2
Tsuruo, T.3
-
16
-
-
52949139387
-
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
-
Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 7:2955-2966
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 2955-2966
-
-
Zabludoff, S.D.1
Deng, C.2
Grondine, M.R.3
Sheehy, A.M.4
Ashwell, S.5
Caleb, B.L.6
Green, S.7
Haye, H.R.8
Horn, C.L.9
Janetka, J.W.10
Liu, D.11
Mouchet, E.12
Ready, S.13
Rosenthal, J.L.14
Queva, C.15
Schwartz, G.K.16
Taylor, K.J.17
Tse, A.N.18
Walker, G.E.19
White, A.M.20
more..
-
17
-
-
77950650401
-
In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762
-
Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff Z, Cook JA (2010) In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 16:2076-2084
-
(2010)
Clin Cancer Res
, vol.16
, pp. 2076-2084
-
-
Mitchell, J.B.1
Choudhuri, R.2
Fabre, K.3
Sowers, A.L.4
Citrin, D.5
Zabludoff, Z.6
Cook, J.A.7
-
18
-
-
84856709250
-
-
AstraZeneca (2011) Global policy: bioethics. http://www.astrazeneca.com/ Responsibility/Code-policies-standards/ Our-global-policies
-
(2011)
Global Policy: Bioethics
-
-
-
19
-
-
0003403775
-
-
3rd edn. Lippincott, Williams and Wilkins, Philadelphia, USA
-
Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications, 3rd edn. Lippincott, Williams and Wilkins, Philadelphia, USA
-
(1995)
Clinical Pharmacokinetics: Concepts and Applications
-
-
Rowland, M.1
Tozer, T.N.2
-
20
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
Van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
21
-
-
77953770987
-
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair
-
Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, Canman CE, Normolle DP, Zabludoff SD, Maybaum J, Lawrence TS (2010) Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res 70:4972-4981
-
(2010)
Cancer Res
, vol.70
, pp. 4972-4981
-
-
Morgan, M.A.1
Parsels, L.A.2
Zhao, L.3
Parsels, J.D.4
Davis, M.A.5
Hassan, M.C.6
Arumugarajah, S.7
Hylander-Gans, L.8
Morosini, D.9
Simeone, D.M.10
Canman, C.E.11
Normolle, D.P.12
Zabludoff, S.D.13
Maybaum, J.14
Lawrence, T.S.15
-
22
-
-
84872494989
-
Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors
-
abst 3033
-
Ho AL, Bendell JC, Cleary JM, Schwartz GK, Burris HA, Oakes P, Agbo F, Barker PN, Senderowicz AM, Shapiro G (2011) Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors. J Clin Oncol 29(15S):abst 3033
-
(2011)
J Clin Oncol
, vol.29
, Issue.15 S
-
-
Ho, A.L.1
Bendell, J.C.2
Cleary, J.M.3
Schwartz, G.K.4
Burris, H.A.5
Oakes, P.6
Agbo, F.7
Barker, P.N.8
Senderowicz, A.M.9
Shapiro, G.10
-
23
-
-
84883487392
-
Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors
-
Seto T, Esaki T, Hirai T, Arita S, Nosaki K, Makiyama A, Kometani T, Fujimoto C, Hamatake M, Takeoka H, Agbo F, Shi X (2013) Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 72:619-627
-
(2013)
Cancer Chemother Pharmacol
, vol.72
, pp. 619-627
-
-
Seto, T.1
Esaki, T.2
Hirai, T.3
Arita, S.4
Nosaki, K.5
Makiyama, A.6
Kometani, T.7
Fujimoto, C.8
Hamatake, M.9
Takeoka, H.10
Agbo, F.11
Shi, X.12
-
24
-
-
0034659341
-
Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice
-
Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T, Ikeda K, Nakayama K, Nakanishi M, Nakayama K (2000) Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev 14:1439-1447 (Pubitemid 30421837)
-
(2000)
Genes and Development
, vol.14
, Issue.12
, pp. 1439-1447
-
-
Takai, H.1
Tominaga, K.2
Motoyama, N.3
Minamishima, Y.A.4
Nagahama, H.5
Tsukiyama, T.6
Ikeda, K.7
Nakayama, K.8
Nakanishi, M.9
Nakayama, K.-I.10
-
26
-
-
84875582236
-
+-ATPase is critical for skeletal and heart muscle function in zebrafish
-
+-ATPase is critical for skeletal and heart muscle function in zebrafish. J Cell Sci 125:6166-6175
-
(2012)
J Cell Sci
, vol.125
, pp. 6166-6175
-
-
Doganli, C.1
Kjaer-Sorensen, K.2
Knoeckel, C.3
Beck, H.C.4
Nyengaard, J.R.5
Honore, B.6
Nissen, P.7
Ribera, A.8
Oxvig, C.9
Lykke-Hartmann, K.10
-
27
-
-
84871234067
-
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor SCH 900776 in refractory acute leukemias
-
Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten K, Peterson KL, Schneider P, Mackey K, Freshwater T, Levis M, McDevitt M, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Issacs R, Kaufmann SH (2012) Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor SCH 900776 in refractory acute leukemias. Clin Cancer Res 18:6723-6731
-
(2012)
Clin Cancer Res
, vol.18
, pp. 6723-6731
-
-
Karp, J.E.1
Thomas, B.M.2
Greer, J.M.3
Sorge, C.4
Gore, S.D.5
Pratz, K.W.6
Smith, B.D.7
Flatten, K.8
Peterson, K.L.9
Schneider, P.10
Mackey, K.11
Freshwater, T.12
Levis, M.13
McDevitt, M.14
Carraway, H.E.15
Gladstone, D.E.16
Showel, M.M.17
Loechner, S.18
Parry, D.A.19
Horowitz, J.A.20
Issacs, R.21
Kaufmann, S.H.22
more..
|